SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001214659-22-014779
Filing Date
2022-12-12
Accepted
2022-12-12 16:31:01
Documents
56
Period of Report
2022-10-31

Document Format Files

Seq Description Document Type Size
1 r12522010q.htm   iXBRL 10-Q 792573
2 EXHIBIT 31.1 ex31_1.htm EX-31.1 7918
3 EXHIBIT 31.2 ex31_2.htm EX-31.2 7852
4 EXHIBIT 32.1 ex32_1.htm EX-32.1 5357
  Complete submission text file 0001214659-22-014779.txt   3870074

Data Files

Seq Description Document Type Size
5 XBRL SCHEMA FILE alxneuro-20221031.xsd EX-101.SCH 39312
6 XBRL CALCULATION FILE alxneuro-20221031_cal.xml EX-101.CAL 35328
7 XBRL DEFINITION FILE alxneuro-20221031_def.xml EX-101.DEF 139430
8 XBRL LABEL FILE alxneuro-20221031_lab.xml EX-101.LAB 287783
9 XBRL PRESENTATION FILE alxneuro-20221031_pre.xml EX-101.PRE 221613
50 EXTRACTED XBRL INSTANCE DOCUMENT r12522010q_htm.xml XML 521120
Mailing Address 3500 LENOX RD. NE SUITE 1500 ATLANTA GA 30326
Business Address 3500 LENOX RD. NE SUITE 1500 ATLANTA GA 30326 844-722-6333
Alzamend Neuro, Inc. (Filer) CIK: 0001677077 (see all company filings)

IRS No.: 811822909 | State of Incorp.: DE | Fiscal Year End: 0430
Type: 10-Q | Act: 34 | File No.: 001-40483 | Film No.: 221457479
SIC: 2834 Pharmaceutical Preparations